Effects of pulse methylprednisolone and oral methylprednisolone treatments on serum levels of oxidative stress markers in Graves' ophthalmopathy
- PMID: 21044110
- DOI: 10.1111/j.1365-2265.2010.03904.x
Effects of pulse methylprednisolone and oral methylprednisolone treatments on serum levels of oxidative stress markers in Graves' ophthalmopathy
Abstract
Background: Recent evidence has shown that oxidative stress may play a role in the pathogenesis of autoimmune diseases, and this is an issue of considerable research interest in the field of infiltrative ophthalmopathy. Therefore, we evaluated both the relationship between Graves' ophthalmopathy (GO) and serum levels of certain indicators of oxidative stress, and the effects of methylprednisolone treatment on serum malondialdehyde (MDA) and glutathione (GSH) levels in patients with euthyroid GO.
Materials and methods: We compared GO patients to both Graves' patients without ophthalmopathy and healthy controls. Ultimately, we assessed four subject groups. Graves' patients with ophthalmopathy (GO) were subcategorized into two groups: Group A subjects (n = 18) were given intravenous glucocorticoid and Group B patients (n = 15) were given oral glucocorticoid. Graves' patients without ophthalmopathy comprised Group C (n = 20), and healthy controls comprised Group D (n = 15). Serum levels of MDA and GSH were measured at baseline and after 4 and 24 weeks of observation via spectrophotometric methods.
Results: We found that serum MDA levels were significantly higher in the two GO groups (Groups A and B) than in GO patients without ophthalmopathy or healthy controls. Conversely, GSH levels were significantly lower in the two GO groups than in Groups C and D. MDA and GSH levels were not different between the latter two groups. MDA levels were strongly and positively correlated with a clinical activity score (CAS). In Group A, MDA levels and the CAS were significantly lower than in Group B at 4 weeks. After 24 weeks, however, MDA levels and the CAS were similar in these two groups.
Conclusion: Oxidative stress appears to be involved in the pathophysiology of GO. Relative to oral dosing, the intravenous administration of a glucocorticoid seems to yield more rapid improvement in disease activity. MDA might be useful as an indicator of clinical activity.
© 2010 Blackwell Publishing Ltd.
Comment in
-
Autoimmunity: graves ophthalmopathy: is oxidative stress the cause?Nat Rev Endocrinol. 2011 Feb;7(2):62. doi: 10.1038/nrendo.2010.219. Nat Rev Endocrinol. 2011. PMID: 21332091 No abstract available.
Similar articles
-
Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophthalmopathy treated with corticosteroids.Immunol Lett. 2004 May 15;93(2-3):227-32. doi: 10.1016/j.imlet.2004.03.020. Immunol Lett. 2004. PMID: 15158621 Clinical Trial.
-
The effect of methylprednisolone pulse treatment on cytokine network in Graves ophthalmopathy.Curr Eye Res. 2007 Mar;32(3):291-7. doi: 10.1080/02713680601186698. Curr Eye Res. 2007. PMID: 17453949
-
Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.J Endocrinol Invest. 2016 Jan;39(1):63-72. doi: 10.1007/s40618-015-0322-7. Epub 2015 Jun 11. J Endocrinol Invest. 2016. PMID: 26062519 Free PMC article.
-
[Steroid therapy for Graves' ophthalmopathy].Nihon Rinsho. 2006 Dec;64(12):2279-85. Nihon Rinsho. 2006. PMID: 17154092 Review. Japanese.
-
[Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].Med Klin (Munich). 2004 Feb 15;99(2):71-6. doi: 10.1007/s00063-004-1014-9. Med Klin (Munich). 2004. PMID: 14963657 Review. German.
Cited by
-
Tears as a Source of Biomarkers in the Diagnosis of Graves' Orbitopathy.Biomolecules. 2022 Nov 2;12(11):1620. doi: 10.3390/biom12111620. Biomolecules. 2022. PMID: 36358969 Free PMC article. Review.
-
Corticosteroids for Graves' Ophthalmopathy: Systematic Review and Meta-Analysis.Biomed Res Int. 2018 Nov 22;2018:4845894. doi: 10.1155/2018/4845894. eCollection 2018. Biomed Res Int. 2018. PMID: 30596092 Free PMC article.
-
Challenges in early identification of causes and treatment of cholestasis in patients with hyperthyroidism: a case report and literature review.J Int Med Res. 2020 Mar;48(3):300060519891018. doi: 10.1177/0300060519891018. Epub 2019 Dec 16. J Int Med Res. 2020. PMID: 31840543 Free PMC article. Review.
-
Antioxidant Therapy in Graves' Orbitopathy.Front Endocrinol (Lausanne). 2020 Dec 14;11:608733. doi: 10.3389/fendo.2020.608733. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33381085 Free PMC article. Review.
-
Oxidative stress in graves' disease.Eur Thyroid J. 2012 Jul;1(2):80-7. doi: 10.1159/000337976. Epub 2012 Jun 7. Eur Thyroid J. 2012. PMID: 24783001 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources